Cargando…

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

Detalles Bibliográficos
Autores principales:	Prat, Aleix, Adamo, Barbara, Fan, Cheng, Peg, Vicente, Vidal, Maria, Galván, Patricia, Vivancos, Ana, Nuciforo, Paolo, Palmer, Héctor G., Dawood, Shaheenah, Rodón, Jordi, Cajal, Santiago Ramon y, Campo, Josep Maria Del, Felip, Enriqueta, Tabernero, Josep, Cortés, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323651/ https://www.ncbi.nlm.nih.gov/pubmed/25670223 http://dx.doi.org/10.1038/srep08179

Ejemplares similares

Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity
por: Prat, Aleix, et al.
Publicado: (2013)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Gene expression‐based classifications of fibroadenomas and phyllodes tumours of the breast
por: Vidal, Maria, et al.
Publicado: (2015)

Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study
por: Carreras, Maria-Josep, et al.
Publicado: (2023)

Breast and gastrointestinal cancer updates from ASCO 2015
por: Dawood, Shaheenah
Publicado: (2015)

Updates from the 2014 San antonio breast cancer symposium
por: Dawood, Shaheenah
Publicado: (2015)

Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
por: Dienstmann, Rodrigo, et al.
Publicado: (2017)

American Society of Clinical Oncology 2014: Updates in breast and gastrointestinal cancers
por: Dawood, Shaheenah
Publicado: (2014)

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Frigola, Joan, et al.
Publicado: (2021)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
por: Serna, Garazi, et al.
Publicado: (2019)

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation
por: Cedrés, Susana, et al.
Publicado: (2018)

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2022)

Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
por: Dienstmann, Rodrigo, et al.
Publicado: (2020)

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2015)

Updates from Gastrointestinal ASCO 2015
por: Dawood, Shaheenah
Publicado: (2015)

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
por: Pernas, Sonia, et al.
Publicado: (2021)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

Beyond molecular tumor heterogeneity: protein synthesis takes control
por: Ramon y Cajal, Santiago, et al.
Publicado: (2018)

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022)

Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
por: Prat, Aleix, et al.
Publicado: (2014)

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
por: Tamborero, David, et al.
Publicado: (2018)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Early-Stage Breast Cancer Detection in Breast Milk
por: Saura, Cristina, et al.
Publicado: (2023)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

New clinical trial designs in the era of precision medicine
por: Garralda, Elena, et al.
Publicado: (2019)

Negative Effects On Cancer Care Due To COVID-19 Implications: Observations From A Cancer Center In The UAE
por: Dawood, Shaheenah, et al.
Publicado: (2020)

Editorial: Multidisciplinary management of cancer patients with immune-related adverse events from checkpoint inhibitors
por: Riveiro-Barciela, Mar, et al.
Publicado: (2023)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer
por: Serna, Garazi, et al.
Publicado: (2020)

Cytokeratin Profile of Basal Cell Carcinomas According to the Degree of Sun Exposure and to the Anatomical Localization
por: García-de-la-Fuente, Mª Reyes, et al.
Publicado: (2018)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
por: Brasó-Maristany, Fara, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic in the early-onset colorectal cancer
por: Baraibar, Iosune, et al.
Publicado: (2023)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Deconstructing the molecular portraits of breast cancer
por: Prat, Aleix, et al.
Publicado: (2010)

Treatment-related mortality with aflibercept in cancer patients
por: Tabernero, Josep, et al.
Publicado: (2014)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations
por: Tabernero, Josep
Publicado: (2019)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9iii1ismfjlts7b6i3e7tbvaol